SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:19265e9e-af48-464f-85ac-843b0c09abb7"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:19265e9e-af48-464f-85ac-843b0c09abb7" > Use, patient select...

Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries

Danchin, Nicolas (författare)
Paris Descartes University
Lettino, Maddalena (författare)
Humanitas Research Hospital
Zeymer, Uwe (författare)
Institute for Cardiac Arrest Research, Ludwigshafen
visa fler...
Widimsky, Petr (författare)
Charles University in Prague
Bardaji, Alfredo (författare)
Hospital Joan XXIII
Barrabes, Jose A. (författare)
Vall d'Hebron University Hospital
Cequier, Angel (författare)
Bellvitge University Hospital-IDIBELL
Claeys, Marc J. (författare)
Antwerp University Hospital
De Luca, Leonardo (författare)
European Hospital
Dörler, Jakob (författare)
Medical University of Innsbruck
Erlinge, David (författare)
Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
Erne, Paul (författare)
University of Zurich
Goldstein, Patrick (författare)
Lille University Hospital
Koul, Sasha M. (författare)
Skåne University Hospital
Lemesle, Gilles (författare)
Lille University Hospital
Lüscher, Thomas F. (författare)
University Hospital of Zurich
Matter, Christian M. (författare)
University Hospital of Zurich
Montalescot, Gilles (författare)
Pitié Salpetriere University Paris
Radovanovic, Dragana (författare)
University of Zurich
Sendón, Jose Lopez (författare)
University Hospital La Paz
Tousek, Petr (författare)
Charles University in Prague
Weidinger, Franz (författare)
Hospital Rudolfstiftung
Weston, Clive F.M. (författare)
Swansea University
Zaman, Azfar (författare)
University of Newcastle upon Tyne
Andell, Pontus (författare)
Skåne University Hospital
Li, Jin (författare)
University Hospital of Zurich
Jukema, J. Wouter (författare)
Leiden University Medical Centre
visa färre...
 (creator_code:org_t)
 
Oxford University Press, 2016
2016
Engelska 16 s.
Ingår i: European Heart Journal - Cardiovascular Pharmacotherapy. - : Oxford University Press. - 2055-6837. ; 2:3, s. 152-167
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries. Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registrieswere heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09-3.55% inhospital (8 registries), 0.09-1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-Threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). Conclusions Real-world evidence from European contemporary registries shows that death, ischaemic events, and bleeding rates are lower than those reported in Phase III studies of P2Y12 inhibitors. Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-Treated patients. These findings are partly related to the fact that the newer agents are used in younger and less ill patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Acute coronary syndromes
Antiplatelet agents
Clopidogrel
Effectiveness
Methodology
Observational
P2Y12 receptor inhibitors
Prasugrel
Real-world evidence
Safety
St-segment elevationmyocardial infarction
Ticagrelor

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy